Roche Holding AG (RHHBF)
| Market Cap | 306.97B |
| Revenue (ttm) | 79.83B |
| Net Income (ttm) | 11.86B |
| Shares Out | n/a |
| EPS (ttm) | 14.77 |
| PE Ratio | 25.89 |
| Forward PE | 15.01 |
| Dividend | 10.97 (2.95%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 19 |
| Average Volume | 371 |
| Open | 368.00 |
| Previous Close | 383.16 |
| Day's Range | 365.45 - 381.00 |
| 52-Week Range | 280.85 - 395.28 |
| Beta | 0.18 |
| RSI | 52.95 |
| Earnings Date | Oct 20, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagn... [Read more]
Financial Performance
In 2024, Roche Holding AG's revenue was 62.40 billion, an increase of 3.23% compared to the previous year's 60.44 billion. Earnings were 8.28 billion, a decrease of -28.01%.
Financial numbers in CHF Financial StatementsNews
Roche licenses cancer candidate from China’s Hansoh Pharma
Roche Wins CHMP Support For Gazyva/Gazyvaro For Lupus Nephritis Treatment
(RTTNews) - Roche Holding AG (RHHBY.PK), Friday announced the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has recommended the approval of Gazyva/Gazyvaro in comb...
CHMP recommends EU approval of Roche's Gazyva/Gazyvaro for lupus nephritis
Basel, 17 October, 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
The Zacks Analyst Blog Highlights NVIDIA, Roche, Lam Research, Tredegar and Kewaunee Scientific
NVIDIA, Roche, and Lam Research lead this week's top Zacks research picks, while Tredegar and Kewaunee Scientific highlight strong niche and microcap opportunities.
Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals
Two Chinese drug developers have signed licensing deals that could yield as much as US$2.5 billion in performance-based payments, underscoring growing international confidence in China’s life sciences...
China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche
Chinese biotech Hansoh Pharma said on Friday its units have signed a license agreement worth up to $1.45 billion with Roche's subsidiary for an investigational treatment of colorectal cancer and other...
Top Stock Reports for NVIDIA, Roche & Lam Research
NVIDIA, Roche, and Lam Research lead today's top Zacks reports, showcasing standout growth drivers and sector-specific strengths.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)
BALA CYNWYD, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Roche (RHHBY) Launches Discount Program for Flu Drug Xofluza
Roche (RHHBY) Launches Discount Program for Flu Drug Xofluza
Roche to sell flu pill for $50 to cash-paying US patients
Roche on Thursday launched direct-to-consumer U.S. sales of its influenza antiviral pill Xofluza at a discounted cash price of $50, following similar moves by rivals as they scramble to address pressu...
Genentech to sell flu pill directly to some consumers at a discount as Trump pressures drugmakers
Roche's Genentech said it will sell its flu pill, Xofluza, directly to certain patients at a discount in a bid to expand access to uninsured people, those with limited coverage or people whose plans d...
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the company's first Direct-to-Patient (DTP) program. This program, wh...
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025
Basel, 16 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented major updates on its innovative sequencing by expansion (SBX) technology at the American Society of Human Genetics (ASHG) 2025 Ann...
Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?
Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.
Wall Street Breakfast Podcast: Papa John's Delivers A Hot Slice
Papa John's soars after report of takeover offer. Roche, Eli Lilly Alzheimer's blood diagnostic test wins FDA approval. Japanese payment app PayPay valuation to likely exceed $20B in US IPO.
Eli Lilly (LLY) and Roche's Blood Test for Alzheimer's Gets FDA Nod
Eli Lilly (LLY) and Roche's Blood Test for Alzheimer's Gets FDA Nod
Roche, Eli Lilly Alzheimer's blood diagnostic test wins FDA approval
Roche Holding's Blood-Based Alzheimer's Test Wins US FDA Approval
(RTTNews) - Roche Holding AG (RHHBY.PK), Monday announced that the U.S. Food and Drug Administration has cleared its Elecsys pTau181 test, a blood-based Alzheimer's test indicated as an aid in the ini...
Roche, Lilly's blood test for Alzheimer's diagnosis gets US approval
Roche Diagnostics said on Monday the U.S. Food and Drug Administration cleared its and partner Eli Lilly's blood test as an aid in the initial assessment for Alzheimer's disease.
Roche's Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer's-related amyloid pathology
Rules out Alzheimer's pathology in early stages to enhance diagnostic pathway efficiency Provides new opportunity to broaden access and improve referral quality Features as part of Roche's growing por...
Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present more than 30 abstracts across more than 10 cance...
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (E...
Roche setback in Delhi HC paves way for cheaper spinal muscular atrophy (SMA) drug
The Delhi High Court has dismissed Roche's appeal, allowing Natco to launch a generic version of Risdiplam for spinal muscular atrophy. This decision prioritizes public health and patient access over ...
HC bins Roche's injunction plea, allows generic version of only drug for SMA
India News: A division bench of Delhi high court Thursday rejected the appeal of pharma giant, Roche, seeking an injunction against Indian pharma company Natco Ph.
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market
Roche has a promising GLP-1 drug that is entering phase 3 trials.